Holen Sie sich die Stockscreener-App
438.85
2.00%
8.62
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$430.23
Offen:
$432.87
24-Stunden-Volumen:
623.27K
Relative Volume:
0.46
Marktkapitalisierung:
$95.17B
Einnahmen:
$201.11B
Nettoeinkommen (Verlust:
$4.95B
KGV:
19.51
EPS:
22.4991
Netto-Cashflow:
$6.29B
1W Leistung:
+3.19%
1M Leistung:
+6.79%
6M Leistung:
+37.42%
1J Leistung:
+23.94%
1-Tages-Spanne:
$431.09
$440.61
1-Wochen-Bereich:
$421.78
$435.50
52-Wochen-Spanne:
$274.84
$440.61
Elevance Health Inc Stock (ELV) Company Profile
Firmenname
Elevance Health Inc
Sektor
Branche
Telefon
(800) 331-1476
Adresse
220 VIRGINIA AVENUE, INDIANAPOLIS
Compare ELV vs UNH, CVS, CI, HUM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELV
Elevance Health Inc
|
438.85 | 95.17B | 201.11B | 4.95B | 6.29B | 22.50 |
UNH
Unitedhealth Group Inc
|
421.31 | 378.16B | 450.13B | 14.91B | 23.62B | 15.55 |
CVS
Cvs Health Corp
|
94.35 | 120.67B | 407.94B | 2.90B | 7.39B | 2.2771 |
CI
Cigna Group
|
305.49 | 80.72B | 278.13B | 6.74B | 7.66B | 23.60 |
HUM
Humana Inc
|
428.82 | 51.49B | 137.20B | 1.15B | 1.27B | 9.3439 |
Elevance Health Inc Stock (ELV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-04-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2026-04-08 | Eingeleitet | Evercore ISI | In-line |
| 2026-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-10-14 | Eingeleitet | Goldman | Neutral |
| 2025-07-21 | Herabstufung | Argus | Buy → Hold |
| 2025-07-18 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-04-15 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-03-17 | Hochstufung | Argus | Hold → Buy |
| 2025-01-22 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2024-10-18 | Herabstufung | Argus | Buy → Hold |
| 2024-07-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-06-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-06 | Eingeleitet | Barclays | Overweight |
| 2023-07-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-28 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-09-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
Alle ansehen
Elevance Health Inc Aktie (ELV) Neueste Nachrichten
Earnings To Watch: Elevance Health (ELV) Reports Q3 Results Tomorrow - Yahoo Finance
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Elevance Health Inc expected to post earnings of $4.68 a shareEarnings Preview - TradingView
Guggenheim raises target for Elevance Health stock from USD 455 to USD 460 - ad-hoc-news.de
Elevance Health: Why I Don't Believe In The Stock At This Price (NYSE:ELV) - Seeking Alpha
Unveiling Elevance Health (ELV) Q3 Outlook: Wall Street Estimates for Key Metrics - Yahoo Finance
Elevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results? - Zacks Investment Research
Elevance Q3 Earnings Preview: Will Lower Premiums Weigh on Results? - TradingView
Centene's Gold Card Push Could Ease CostsBut Will Savings Follow? - Zacks Investment Research
Elevance Health options signal 6.8% move on Oct. 21 earnings - Investing.com
Elevance Health Foundation Announces Winners of Inaugural Patient Safety Prize Through Innovative Community Action Leadership Program - Business Wire
Oscar Health Raises 2026 Operating Earnings Outlook as Margins Improve - Zacks Investment Research
Is Oscar Health Stock a Buy as Growth Surges but Valuation Stays Rich? - Zacks Investment Research
Oscar Health Rallies 14.9% in 3 Months: Can the Gains Keep Going? - Zacks Investment Research
Elevance Health, Inc. (ELV) Stock Forecasts - Yahoo Finance
Elevance Health Inc. stock outperforms competitors on strong trading day - MarketWatch
Elevance Health, Inc. (ELV) Stock Forecasts - Yahoo! Finance Canada
Has Elevance Health (ELV) Earned Its Discount After Medicare Updates? - Yahoo Finance
Elevance Health Inc. stock outperforms competitors on strong trading day - MarketWatch
CVS Health Trades at a Discount to Industry: How to Play the Stock? - Zacks Investment Research
2 Stocks to Buy Hand Over Fist in October - The Motley Fool
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy? - Zacks Investment Research
UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore - Zacks Investment Research
Elevance Health Inc. stock outperforms competitors on strong trading day - MarketWatch
Elevance Health stock sets October 21 earnings date - AD HOC NEWS
Third-quarter results are set for 6 a.m. Oct. 21, before Elevance Health's 8:30 a.m. call. - Stock Titan
Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026 - Yahoo Finance
Elevance Health, Inc. Actuals & Estimates (NYSE:ELV) - TradingView
ANTM5405194 Bond Profile: Coupon and Redemption - TradingView
Elevance Health Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year? - Zacks Investment Research
Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year? - Yahoo Finance
Elevance Health, Inc. (ELV) Stock Forecasts - Yahoo Finance
Elevance Health Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Elevance Health (ELV): Conviction Pays Off as Underwriting Disciplines Stabilize Margins - Yahoo Finance
Elevance Health Unveils 2027 Medicare Advantage Plans, Ticker EL - GuruFocus
Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support - Business Wire
Elevance Health (ELV) Is Back In The Spotlight, What Is Drawing Attention? - Simply Wall Street
Elevance Health, Inc. (ELV) Stock forecasts - Yahoo Finance Singapore
Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support - Yahoo Finance
ANTM5815521 Bond Profile: Coupon and Redemption - TradingView
ANTM3707029 Bond Profile: Coupon and Redemption - TradingView
ANTM3684374 Bond Profile: Coupon and Redemption - TradingView
Elevance Health's Quarterly Earnings Preview: What You Need to Know - inkl
Elevance Health's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
AE1J Bond Profile: Coupon and Redemption - TradingView
Free cash flow per share of Elevance Health, Inc. – HAN:A58 - TradingView
Elevance Health on Pace for Longest Losing Streak Since September 2022 -- Data Talk - Moomoo
ANTM3670950 Bond Profile: Coupon and Redemption - TradingView
ANTM4880736 Bond Profile: Coupon and Redemption - TradingView
Finanzdaten der Elevance Health Inc-Aktie (ELV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Elevance Health Inc-Aktie (ELV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BOUDREAUX GAIL | President and CEO |
Jul 17 '26 |
Buy |
367.79 |
2,725 |
1,002,230 |
171,976 |
| CLARK R KERRY | Director |
Jul 07 '26 |
Proposed Sale |
419.91 |
1,500 |
629,865 |
0 |
| Penczek Ronald W | CAO & Controller |
Jun 12 '26 |
Sale |
403.16 |
369 |
148,766 |
3,740 |
| RONALD WILLIAM PENCZEK | Officer |
Jun 12 '26 |
Proposed Sale |
403.16 |
369 |
148,767 |
0 |
| Dixon Robert L JR | Director |
Jun 11 '26 |
Proposed Sale |
401.76 |
151 |
60,666 |
0 |
| Dixon Robert L JR | Director |
Jun 11 '26 |
Sale |
401.77 |
151 |
60,667 |
10,734 |
| Penczek Ronald W | CAO & Controller |
May 19 '26 |
Option Exercise |
294.30 |
1,531 |
450,579 |
5,640 |
| Penczek Ronald W | CAO & Controller |
May 19 '26 |
Sale |
403.13 |
1,531 |
617,192 |
4,109 |
| RONALD WILLIAM PENCZEK | Officer |
May 19 '26 |
Proposed Sale |
403.13 |
1,531 |
617,192 |
0 |
| SCHULMAN AMY W | Director |
Mar 12 '26 |
Sale |
287.50 |
26 |
7,475 |
218 |
2.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):